基本信息 产品详情 公司简介 推荐产品
网站主页 阿得贝利单抗 HTI-1088, SHR-1316
  • (Adebrelimab)Biosimilar Reference Antibody-GS40011
  • (Adebrelimab)Biosimilar Reference Antibody-GS40011

1/2

(Adebrelimab)Biosimilar Reference Antibody-GS40011 新品

Adebrelimab
300 100μg 起订
湖北 更新日期:2026-03-12

武汉迈思生物科技有限公司

VIP1年
联系人:市场
电话:027-65523427拨打
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

中文名称:
HTI-1088, SHR-1316
英文名称:
Adebrelimab
CAS号:
2247114-85-6
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Genetically human
偶联物:
靶点:
PDL1/CD274
免疫原:
PDL1/CD274
亚型:
IgG4 - kappa
验证方法:
(Adebrelimab)Biosimilar Reference Antibody(GS40011) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

货号:GS40011

Adebrelimab is a fully human IgG4 monoclonal antibody targeting the programmed cell death ligand 1 (PD-L1). It functions as an immune checkpoint inhibitor by specifically binding to PD-L1, thereby blocking its interaction with the PD-1 and B7.1 (CD80) receptors on immune cells. This blockade releases the "brakes" on the immune system, particularly on T cells, restoring their ability to recognize and attack tumor cells. Developed by Jiangsu Hengrui Medicine, it is approved in China and is in global clinical trials for various cancers, most notably in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), where it has demonstrated significant survival benefits.





Adebrelimab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 100万以内
经营模式 试剂
主营行业 抗体,蛋白组学

HTI-1088, SHR-1316相关厂家报价

内容声明
拨打电话 立即询价